DUBLIN, Ireland — Warner Chilcott has been cleared by the Food and Drug Administration to market 200-mg strength of Doryx delayed-release tablets.
The Ireland-based pharmaceutical company said Friday that it expects the commercial launch of the Doryx tablets to take place in July.
A tetracycline-class oral antibiotic, Doryx (doxycycline hyclate) is used to treat a range of bacterial infections, such as urinary tract infections, acne, gonorrhea, chlamydia, periodontitis. It’s also used to treat blemishes, bumps and acne-like lesions caused by rosacea.
